Aquilo Capital Management, LLC
CIK 1591986 · View on SEC EDGAR ↗
- Portfolio value
- $55.8M
- Positions
- 13
- As of
- March 31, 2025 Data as of Q1 2025
#8,675 of 9,443 by 13F value · top 91.9%
Portfolio value QoQ: -15.9% 13F does not disclose cash
- Top 10 holdings weight
- 93.44%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 13
- Effective number of positions
- 6.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q1 2025: 18.25% Est. buys $13,286,924 · sells $11,138,030
- New positions
- 1
- Increased
- 4
- Decreased
- 7
- Closed
- 2
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Sector breakdown
Healthcare
86.7%
Other/Unmapped
13.3%
Full portfolio 13 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| AMGN Amgen Inc. - Common Stock | $18,693,000 | 33.51% | 60,000 | Call option | $12,177,000 | Up ×1 | |
| BPMC | $7,428,290 | 13.32% | 83,926 | $-3,875,422 | Down ×1 | ||
| ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | $7,008,656 | 12.57% | 550,130 | $-6,294,017 | Down ×1 | ||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $3,950,625 | 7.08% | 81,692 | $994,174 | Up ×1 | ||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $3,791,320 | 6.80% | 138,521 | $-3,591,730 | Down ×1 | ||
| DTIL Precision BioSciences, Inc. - Common Stock | $3,463,731 | 6.21% | 726,149 | $1,420,138 | Up ×1 | ||
| ARVN Arvinas, Inc. - Common Stock | $2,532,577 | 4.54% | 360,766 | $-3,769,867 | Up ×1 | ||
| RGNX REGENXBIO Inc. - Common Stock | $1,939,809 | 3.48% | 271,302 | $-737,105 | Down ×1 | ||
| ACET Adicet Bio, Inc. - Common Stock | $1,854,426 | 3.32% | 2,456,194 | $-580,583 | Down ×1 | ||
| BCYC Bicycle Therapeutics plc - American Depositary Shares | $1,457,691 | 2.61% | 171,695 | $-1,649,063 | Down ×1 | ||
| IMTX Immatics N.V. - Ordinary Shares | $1,375,108 | 2.47% | 304,902 | $-1,283,335 | Down ×1 | ||
| RPTX Repare Therapeutics Inc. - Common Shares | $1,275,474 | 2.29% | 1,293,715 | $-419,293 | |||
| ZYME Zymeworks Inc. - Common Stock | $1,006,181 | 1.80% | 84,482 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| ZYME | $1,006,181 | 84,482 | 1.80% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| AMGN | Bought more | +35K | +$12.2M |
| ARWR | Trimmed | -157K | -$6.3M |
| BPMC | Trimmed | -46K | -$3.9M |
| ARVN | Bought more | +32K | -$3.8M |
| KYMR | Trimmed | -45K | -$3.6M |
| BCYC | Trimmed | -50K | -$1.6M |
| DTIL | Bought more | +190K | +$1.4M |
| IMTX | Trimmed | -69K | -$1.3M |
| PTGX | Bought more | +5K | +$994K |
| RGNX | Trimmed | -75K | -$737K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.